RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for obesity.

Zura Bio has initiated the Phase II TibuSURE trial to assess tibulizumab, in treating systemic sclerosis (SSc) in adult patients.

Marengo's Phase II trial is assessing T cell activator invikafusp alfa in the treatment of advanced PD-1 resistant solid tumours.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

Jemperli is central to GSK’s immuno-oncology research and development efforts. Credit: GSK. GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) ...